-
1.
公开(公告)号:US07705042B2
公开(公告)日:2010-04-27
申请号:US11255043
申请日:2005-10-20
申请人: Carl R. Illig , Shelley K. Ballentine , Jinsheng Chen , Sanath Meegalla , Jonathan Rudolph , Mark J. Wall , Kenneth J. Wilson , Renee DesJarlais , Carl L. Manthey , Christopher M. Flores , Christopher J. Molloy
发明人: Carl R. Illig , Shelley K. Ballentine , Jinsheng Chen , Sanath Meegalla , Jonathan Rudolph , Mark J. Wall , Kenneth J. Wilson , Renee DesJarlais , Carl L. Manthey , Christopher M. Flores , Christopher J. Molloy
IPC分类号: A61K31/34
CPC分类号: C07D263/34 , C07D207/34 , C07D233/90 , C07D307/68 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12
摘要: The invention relates to arylamide and hetereoarylamide compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
摘要翻译: 本发明涉及式I的芳基酰胺和hetereoarylamide化合物:其中A,X,R 2和W在说明书中列出,以及其互变异构体和药学上可接受的盐,其抑制蛋白酪氨酸激酶,特别是c-fms激酶。 治疗自身免疫性疾病的方法 和具有炎症成分的疾病; 治疗卵巢癌,子宫癌,乳腺癌,结肠癌,胃癌,毛细胞白血病和非小细胞肺癌的转移; 并治疗疼痛,包括由肿瘤转移或骨关节炎引起的骨骼疼痛,或内脏,炎症和神经源性疼痛; 还提供了骨质疏松症,佩吉特氏病和其它骨吸收介导关节炎,假体失败,溶骨性骨肉瘤,骨髓瘤以及与式I化合物对骨的肿瘤转移的其它疾病。
-
公开(公告)号:US07795279B2
公开(公告)日:2010-09-14
申请号:US11550077
申请日:2006-10-17
申请人: Shelley K. Ballentine , Christian Andrew Baumann , Jinsheng Chen , Carl R. Illig , Sanath K. Meegalla , M. Jonathan Rudolph , Robert W. Tuman , Mark J. Wall , Kenneth Wilson , Dana L. Johnson
发明人: Shelley K. Ballentine , Christian Andrew Baumann , Jinsheng Chen , Carl R. Illig , Sanath K. Meegalla , M. Jonathan Rudolph , Robert W. Tuman , Mark J. Wall , Kenneth Wilson , Dana L. Johnson
IPC分类号: A61K31/445 , C07D293/10
CPC分类号: A61K31/4439 , A61K31/454 , A61K31/497 , A61K31/5355 , Y10S514/908
摘要: A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.
摘要翻译: 降低或抑制细胞或受试者中FLT3的激酶活性的方法,以及使用本发明的化合物,在受试者中预防或治疗细胞增殖性病症和/或与FLT3有关的病症的用途:或 其溶剂合物,水合物,互变异构体或其药学上可接受的盐。 本发明还涉及治疗诸如癌症和其它细胞增殖性疾病的病症的方法。
-
公开(公告)号:US08497376B2
公开(公告)日:2013-07-30
申请号:US12252439
申请日:2008-10-16
申请人: Carl R. Illig , Jinsheng Chen , Sanath K. Meegalia , Mark J. Wall
发明人: Carl R. Illig , Jinsheng Chen , Sanath K. Meegalia , Mark J. Wall
IPC分类号: C07D405/14 , C07D471/04 , C07D493/08
CPC分类号: C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D471/08 , C07D493/08
摘要: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
摘要翻译: 本发明涉及式I化合物:其中Z,X,J,R 2和W在本说明书中列出,以及其抑制蛋白酪氨酸激酶,特别是c-型的溶剂化物,水合物,互变异构体和药学上可接受的盐, fms激酶。 治疗自身免疫性疾病的方法 和具有炎症成分的疾病; 治疗卵巢癌,子宫癌,乳腺癌,前列腺癌,肺癌,结肠癌,胃癌,毛细胞白血病的转移; 并治疗疼痛,包括由肿瘤转移或骨关节炎引起的骨骼疼痛,或内脏,炎症和神经源性疼痛; 骨质疏松症,佩吉特氏病和其他疾病,其中骨吸收介导包括类风湿性关节炎和其它形式的炎症性关节炎,骨关节炎,假体衰竭,溶骨性肉瘤,骨髓瘤和肿瘤转移至骨骼的发病率与式I化合物, 也提供。
-
公开(公告)号:US07662837B2
公开(公告)日:2010-02-16
申请号:US11254276
申请日:2005-10-20
申请人: Carl R. Illig , Shelley K. Ballentine , Jinsheng Chen , Sanath K. Meegalla , M. Jonathan Rudolph , Mark J. Wall , Kenneth J. Wilson , Renee L. Desjarlais , Carl L. Manthey , Christopher Flores , Christopher J. Molloy
发明人: Carl R. Illig , Shelley K. Ballentine , Jinsheng Chen , Sanath K. Meegalla , M. Jonathan Rudolph , Mark J. Wall , Kenneth J. Wilson , Renee L. Desjarlais , Carl L. Manthey , Christopher Flores , Christopher J. Molloy
IPC分类号: A61K31/454 , C07D401/02
CPC分类号: C07D307/71 , C07D401/12 , C07D401/14 , C07D407/12 , C07D409/12 , C07D409/14
摘要: The invention is directed to compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
摘要翻译: 本发明涉及式I化合物:其中A,X,R 2和W在本说明书中阐述,以及其抑制蛋白酪氨酸激酶,特别是c-fms激酶的溶剂合物,水合物,互变异构体及其药学上可接受的盐 。 治疗自身免疫性疾病的方法 和具有炎症成分的疾病; 治疗卵巢癌,子宫癌,乳腺癌,结肠癌,胃癌,毛细胞白血病和非小细胞肺癌的转移; 并治疗疼痛,包括由肿瘤转移或骨关节炎引起的骨骼疼痛,或内脏,炎症和神经源性疼痛; 还提供了骨质疏松症,佩吉特氏病和其它骨吸收介导包括关节炎,假体失败,溶骨性骨肉瘤,骨髓瘤以及与式I化合物对骨的肿瘤转移的其它疾病。
-
公开(公告)号:US07326788B2
公开(公告)日:2008-02-05
申请号:US10894940
申请日:2004-07-20
申请人: Mark J. Wall , Mark R. Player , Raymond Joseph Patch , Sanath Meegalla , Jian Liu , Carl R. Illig , Wing Cheung , Jinsheng Chen , Davoud Asgari
发明人: Mark J. Wall , Mark R. Player , Raymond Joseph Patch , Sanath Meegalla , Jian Liu , Carl R. Illig , Wing Cheung , Jinsheng Chen , Davoud Asgari
IPC分类号: C07D215/38 , C07D215/44
CPC分类号: C07D215/227 , C07D401/04 , C07D409/04 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , Y02P20/582
摘要: The invention is directed to compounds of Formulae I and II: wherein R1, R2, R3, R5, R6, Y1, Y2, Y3, Y4 and X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.
摘要翻译: 本发明涉及式I和II的化合物:其中R 1,R 2,R 3,R 5, 其中,R 6,R 6,Y 1,Y 2,Y 3,Y 4, SUP& X和X在本说明书中列出,以及其抑制蛋白酪氨酸激酶,特别是c-fms激酶的溶剂合物,水合物,互变异构体或其药学上可接受的盐。
-
公开(公告)号:US08697716B2
公开(公告)日:2014-04-15
申请号:US11737517
申请日:2007-04-19
申请人: Carl R. Illig , Shelley K. Balltentine , Jinsheng Chen , Sanath K. Meegalla , M. Jonathan Rudolph , Mark J. Wall , Kenneth J. Wilson , Renee L. DesJarlais , Carl L. Manthey , Christopher J. Molloy
发明人: Carl R. Illig , Shelley K. Balltentine , Jinsheng Chen , Sanath K. Meegalla , M. Jonathan Rudolph , Mark J. Wall , Kenneth J. Wilson , Renee L. DesJarlais , Carl L. Manthey , Christopher J. Molloy
IPC分类号: A61K31/41 , A61K31/435
CPC分类号: A61K31/5377 , A61K31/4178 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K45/06 , A61N5/10 , A61N2005/1098 , C07D307/68 , C07D401/12 , C07D401/14 , C07D407/12 , C07D409/12 , C07D409/14 , C12N9/99
摘要: A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.
摘要翻译: 降低或抑制细胞或受试者中C-KIT的激酶活性的方法,以及使用这些化合物在受试者中预防或治疗细胞增殖性疾病和/或与C-KIT相关的病症的方法, 本发明:或其溶剂合物,水合物,互变异构体或其药学上可接受的盐。 本发明还涉及治疗诸如癌症和其它细胞增殖性疾病的病症的方法。
-
公开(公告)号:US07645755B2
公开(公告)日:2010-01-12
申请号:US11408096
申请日:2006-04-20
申请人: Carl R. Illig , Shelley K. Ballentine , Jinsheng Chen , Sanath K. Meegalla , M. Jonathan Rudolph , Mark J. Wall , Kenneth J. Wilson , Renee L. Desjarlais , Carl L. Manthey , Christopher Flores , Christopher J. Molloy
发明人: Carl R. Illig , Shelley K. Ballentine , Jinsheng Chen , Sanath K. Meegalla , M. Jonathan Rudolph , Mark J. Wall , Kenneth J. Wilson , Renee L. Desjarlais , Carl L. Manthey , Christopher Flores , Christopher J. Molloy
IPC分类号: A61K31/5377 , A61K31/454 , C07D413/14 , C07D401/02
CPC分类号: C07D307/71 , A61K45/06 , C07D401/12 , C07D401/14 , C07D407/12 , C07D409/12 , C07D409/14
摘要: The invention is directed to compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
-
公开(公告)号:US20090105296A1
公开(公告)日:2009-04-23
申请号:US12252439
申请日:2008-10-16
申请人: Carl R. Illig , Jinsheng Chen , Sanath K. Meegalia , Mark J. Wall
发明人: Carl R. Illig , Jinsheng Chen , Sanath K. Meegalia , Mark J. Wall
IPC分类号: A61K31/439 , C07D493/08 , C07D471/04 , A61K31/4439 , C07D405/14 , A61K31/4178
CPC分类号: C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D471/08 , C07D493/08
摘要: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
摘要翻译: 本发明涉及式I化合物:其中Z,X,J,R 2和W在本说明书中列出,以及其抑制蛋白酪氨酸激酶,特别是c-型的溶剂化物,水合物,互变异构体和药学上可接受的盐, fms激酶。 治疗自身免疫性疾病的方法 和具有炎症成分的疾病; 治疗卵巢癌,子宫癌,乳腺癌,前列腺癌,肺癌,结肠癌,胃癌,毛细胞白血病的转移; 并治疗疼痛,包括由肿瘤转移或骨关节炎引起的骨骼疼痛,或内脏,炎症和神经源性疼痛; 骨质疏松症,佩吉特氏病和其他疾病,其中骨吸收介导包括类风湿性关节炎和其它形式的炎症性关节炎,骨关节炎,假体衰竭,溶骨性肉瘤,骨髓瘤和肿瘤转移至骨骼的发病率与式I化合物, 也提供。
-
-
-
-
-
-
-